全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Case Report: Long-Term Survival in a Child with Alobar Holoprosencephaly—Developmental Improvement with Supportive Pharmacotherapy

DOI: 10.4236/oalib.1114504, PP. 1-10

Subject Areas: Neurology

Keywords: Holoprosencephaly Alobar Pediatric Neurology Neuroenhancers Improvement

Full-Text   Cite this paper   Add to My Lib

Abstract

Holoprosencephaly (HPE) is a severe congenital brain malformation characterized by incomplete division of the prosencephalon, with the alobar form being the most severe and usually incompatible with long-term survival. Most affected infants die in utero or in the early neonatal period, and those who survive typically show profound neurodevelopmental impairment with minimal progress. Here, we report the case of a male child with MRI-confirmed alobar HPE who presented with seizures, gastroesophageal reflux, and severe developmental delay in early infancy but subsequently achieved partial developmental gains and longterm survival beyond three years. The child was managed with a combination of antiepileptic medications, supportive pharmacological interventions, neuroenhancers, and structured physiotherapy, leading to sustained seizure control, improvement in feeding, reduction of spasticity, and attainment of motor and social milestones including head control, prone-to-supine turning, abdominal crawling, babbling, and social interaction. This report highlights the potential for individualized multimodal management to improve quality of life and extend survival even in severe malformations like alobar HPE, and it underscores the importance of reporting rare cases that challenge existing prognostic expectations.

Cite this paper

Gabr, R. I. (2025). Case Report: Long-Term Survival in a Child with Alobar Holoprosencephaly—Developmental Improvement with Supportive Pharmacotherapy. Open Access Library Journal, 12, e14504. doi: http://dx.doi.org/10.4236/oalib.1114504.

References

[1]  Dubourg, C., Bendavid, C., Pasquier, L., Henry, C., Odent, S. and David, V. (2007) Holoprosencephaly. Orphanet Journal of Rare Diseases, 2, Article No. 8. https://doi.org/10.1186/1750-1172-2-8
[2]  National Institute of Neurologi-cal Disorders and Stroke (2017) Holoprosencephaly Information Page. National Institutes of Health, U.S. Department of Health & Human Services.
[3]  Raam, M.S., Solomon, B.D. and Muenke, M. (2011) Holoprosencephaly: A Guide to Di-agnosis and Clinical Management. Indian Pediatrics, 48, 457-466. https://doi.org/10.1007/s13312-011-0078-x
[4]  Barkovich, A.J., Simon, E.M., Clegg, N.J., Kinsman, S.L., Hahn, J.S., Stashinko, E.E., et al. (2002) Holo-prosencephaly: Classification and MR Imaging Findings. American Journal of Neuroradiology, 23, 459-464.
[5]  Barkovich, A.J. and Quint, D.J. (1993) Mid-dle Interhemispheric Fusion: An Unusual Variant of Holoprosencephaly. Amer-ican Journal of Neuroradiology, 14, 431-440.
[6]  Hahn, J.S. and Plawner, L.L. (2004) Evaluation and Management of Children with Holoprosencephaly. Pedi-atric Neurology, 31, 79-88. https://doi.org/10.1016/j.pediatrneurol.2004.03.006
[7]  Benjamin, R.H., Nguyen, J.M., Canfield, M.A., Shumate, C.J. and Agopian, A.J. (2023) Survival of Neonates, Infants, and Children with Birth Defects: A Population-Based Study in Texas, 1999-2018. The Lancet Regional Health—Americas, 27, Article ID: 100617. https://doi.org/10.1016/j.lana.2023.100617
[8]  Muresanu, D.F., Florian, S., Hömberg, V., Matula, C., von Steinbüchel, N., Vos, P.E., et al. (2020) Efficacy and Safety of Cerebrolysin in Neurorecovery after Moderate-Severe Traumatic Brain Injury: Results from the CAPTAIN II Trial. Neurological Scienc-es, 41, 1171-1181. https://doi.org/10.1007/s10072-019-04181-y
[9]  Zhang, C., et al. (2022) Cerebrolysin Promotes Synaptic Recovery in Pediatric Brain Injury. Child’s Nervous System, 38, 1853-1861.
[10]  Zeisel, S.H. (2006) Choline: Critical Role during Fetal Development and Dietary Requirements in Adults. Annual Review of Nutrition, 26, 229-250. https://doi.org/10.1146/annurev.nutr.26.061505.111156
[11]  Scalabrino, G. (2009) The Multi-Faceted Basis of Vitamin B12 (cobalamin) Neurotrophism in Adult Central Nervous System: Lessons Learned from Its Deficiency. Progress in Neurobiology, 88, 203-220. https://doi.org/10.1016/j.pneurobio.2009.04.004.
[12]  Okada, K., et al. (2023) Methylcobalamin in Neuroregeneration: Experimental and Clinical Per-spectives. Frontiers in Neurology, 14, Article 1123.
[13]  Freiherr, J., Hall-schmid, M., Frey, W.H., Brünner, Y.F., Chapman, C.D., Hölscher, C., et al. (2013) Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 27, 505-514. https://doi.org/10.1007/s40263-013-0076-8.
[14]  Craft, S., et al. (2022) In-tranasal Insulin Therapy for Neurological Recovery. Journal of Pediatric Neu-rology, 20, 221-229.
[15]  Patel, Y.C. (1999) Somatostatin and Its Receptor Family. Frontiers in Neuroendocrinology, 20, 157-198. https://doi.org/10.1006/frne.1999.0183
[16]  Juul, S.E. and Pet, G.C. (2015) Erythropoietin and Neonatal Neuroprotection. Clinics in Perinatology, 42, 469-481. https://doi.org/10.1016/j.clp.2015.04.004
[17]  Barr, M. and Co-hen, M.M. (1999) Holoprosencephaly Survival and Performance. American Journal of Medical Genetics, 89, 116-120. https://doi.org/10.1002/(sici)1096-8628(19990625)89:2<116::aid-ajmg10>3.0.co;2-4
[18]  Mollel, G., Mpayo, L.L., Mkonyi, M.F. and Manji, K.P. (2024) Alobar Holoprosencephaly Survival beyond the Neonatal Period and Associated Comorbidities. Journal of African Neonatology, 2, 56-61.
[19]  Kaliaperumal, C., Ndoro, S., Mandiwanza, T., Reidy, F., McAuliffe, F., Caird, J., et al. (2016) Holo-prosencephaly: Antenatal and Postnatal Diagnosis and Outcome. Child’s Nerv-ous System, 32, 801-809. https://doi.org/10.1007/s00381-016-3015-4
[20]  Kumar, A., et al. (2023) Long-Term Outcome of Holoprosencephaly: A Multicenter Review. European Journal of Paediatric Neurology, 43, 45-54.
[21]  Li, Y., et al. (2024) Supportive Multimodal Management in Congenital Brain Malformations: Impact on Surviv-al. Brain and Development, 46, 275-282.
[22]  Hahn, J.S., Barnes, P.D., Clegg, N.J. and Stashinko, E.E. (2010) Septopreoptic Holoprosencephaly: A Mild Sub-type Associated with Midline Craniofacial Anomalies. American Journal of Neu-roradiology, 31, 1596-1601. https://doi.org/10.3174/ajnr.a2123
[23]  Malta, M., AlMutiri, R., Martin, C.S. and Srour, M. (2023) Holoprosencephaly: Review of Embryology, Clinical Phenotypes, Etiology and Management. Children, 10, Article 647. https://doi.org/10.3390/children10040647
[24]  Solomon, B.D., Lacbawan, F., Mercier, S., Clegg, N.J., Delgado, M.R., Rosenbaum, K., et al. (2009) Mutations in ZIC2 in Human Holoprosencephaly: Description of a Novel ZIC2 Specific Phenotype and Comprehensive Analysis of 157 Individuals. Jour-nal of Medical Genetics, 47, 513-524. https://doi.org/10.1136/jmg.2009.073049

Full-Text


Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133